164 related articles for article (PubMed ID: 15480842)
1. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).
Morrison CE; Borod JC; Brin MF; Hälbig TD; Olanow CW
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1333-41. PubMed ID: 15480842
[TBL] [Abstract][Full Text] [Related]
2. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
Growdon JH; Kieburtz K; McDermott MP; Panisset M; Friedman JH
Neurology; 1998 May; 50(5):1327-31. PubMed ID: 9595982
[TBL] [Abstract][Full Text] [Related]
3. Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease.
Funkiewiez A; Ardouin C; Cools R; Krack P; Fraix V; Batir A; Chabardès S; Benabid AL; Robbins TW; Pollak P
Mov Disord; 2006 Oct; 21(10):1656-62. PubMed ID: 16830317
[TBL] [Abstract][Full Text] [Related]
4. Deep brain stimulation and cognitive functions in Parkinson's disease: A three-year controlled study.
Zangaglia R; Pacchetti C; Pasotti C; Mancini F; Servello D; Sinforiani E; Cristina S; Sassi M; Nappi G
Mov Disord; 2009 Aug; 24(11):1621-8. PubMed ID: 19514093
[TBL] [Abstract][Full Text] [Related]
5. Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial.
Witt K; Granert O; Daniels C; Volkmann J; Falk D; van Eimeren T; Deuschl G
Brain; 2013 Jul; 136(Pt 7):2109-19. PubMed ID: 23801735
[TBL] [Abstract][Full Text] [Related]
6. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.
Funkiewiez A; Ardouin C; Krack P; Fraix V; Van Blercom N; Xie J; Moro E; Benabid AL; Pollak P
Mov Disord; 2003 May; 18(5):524-30. PubMed ID: 12722166
[TBL] [Abstract][Full Text] [Related]
7. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Relja M; Klepac N
J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
[TBL] [Abstract][Full Text] [Related]
8. Functional and effective connectivity in subthalamic local field potential recordings of patients with Parkinson's disease.
Hohlefeld FU; Huchzermeyer C; Huebl J; Schneider GH; Nolte G; Brücke C; Schönecker T; Kühn AA; Curio G; Nikulin VV
Neuroscience; 2013 Oct; 250():320-32. PubMed ID: 23876322
[TBL] [Abstract][Full Text] [Related]
9. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition.
Triantafyllou NI; Nikolaou C; Boufidou F; Angelopoulos E; Rentzos M; Kararizou E; Evangelopoulos ME; Vassilopoulos D
Parkinsonism Relat Disord; 2008; 14(4):321-5. PubMed ID: 18055246
[TBL] [Abstract][Full Text] [Related]
10. Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off".
Bosco D; Plastino M; Bosco F; Fava A; Rotondo A
Minerva Med; 2011 Apr; 102(2):125-32. PubMed ID: 21483399
[TBL] [Abstract][Full Text] [Related]
11. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
[TBL] [Abstract][Full Text] [Related]
12. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
13. Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson's disease.
Gul A; Yousaf J
Singapore Med J; 2019 Aug; 60(8):414-417. PubMed ID: 30246215
[TBL] [Abstract][Full Text] [Related]
14. Semantic activation in Parkinson's disease patients on and off levodopa.
Angwin AJ; Arnott WL; Copland DA; Haire MP; Murdoch BE; Silburn PA; Chenery HJ
Cortex; 2009 Sep; 45(8):950-9. PubMed ID: 19356748
[TBL] [Abstract][Full Text] [Related]
15. Effects of pallidal deep brain stimulation and levodopa treatment on reaction-time performance in Parkinson's disease.
Schubert T; Volkmann J; Müller U; Sturm V; Voges J; Freund HJ; Von Cramon DY
Exp Brain Res; 2002 May; 144(1):8-16. PubMed ID: 11976755
[TBL] [Abstract][Full Text] [Related]
16. Levodopa and the feedback process on set-shifting in Parkinson's disease.
Au WL; Zhou J; Palmes P; Sitoh YY; Tan LC; Rajapakse JC
Hum Brain Mapp; 2012 Jan; 33(1):27-39. PubMed ID: 21438075
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of sustained attention in patients with Parkinson's disease being treated with dopamine precursors].
Luque-Moreno C; López-García JC; Díaz-Argandoña E
Rev Neurol; 2012 Sep; 55(5):257-62. PubMed ID: 22930136
[TBL] [Abstract][Full Text] [Related]
18. Effects of depression and Parkinson's disease on cognitive functioning.
Norman S; Tröster AI; Fields JA; Brooks R
J Neuropsychiatry Clin Neurosci; 2002; 14(1):31-6. PubMed ID: 11884652
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
Hanna-Pladdy B; Pahwa R; Lyons KE
J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
[TBL] [Abstract][Full Text] [Related]
20. [Levodopa and cognitive disorders in Parkinson's disease].
Leiva-Santana C; Alvarez-Saúco M
Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
